[Human Papillomavirus Vaccination: Attitude to a Consultation on a Therapeutic Novelty]

Overview

Journal Aten Primaria

Specialty Public Health

Date 2008 Apr 15

PMID 18405586

Citations 3

Authors

Cesar Alameda Gonzalez

Antonio de Lorenzo-Caceres Ascanio

Affiliations

Soon will be listed here.

Citing Articles

[Acceptance of the HPV vaccination by parents of 10-year old primary schoolgirls. One year later].

Bobe Armant F, Buil Arasanz M, Morro Grau A, Trubat Munoz G Aten Primaria. 2010; 42(12):628-9.

PMID: 20304532 PMC: 7024505. DOI: 10.1016/j.aprim.2010.01.006.

[Acceptance of the HPV vaccine by parents of 11-year old girls].

Bobe Armant F, Buil Arasanz M, Morro Grau A, Trubat Munoz G Aten Primaria. 2009; 41(7):423-4.

PMID: 19427074 PMC: 7021943. DOI: 10.1016/j.aprim.2008.11.016.

[Papilloma virus vaccine].

Puig-Tintore L, Bayas J, Alvarez-Pasquin M Aten Primaria. 2008; 40(11):584-5.

PMID: 19055906 PMC: 7713446. DOI: 10.1157/13128578.

References

Markowitz L, Dunne E, Saraiya M, Lawson H, Chesson H, Unger E . Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56(RR-2):1-24. View

Mao C, Koutsky L, Ault K, Wheeler C, Brown D, Wiley D . Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006; 107(1):18-27. DOI: 10.1097/01.AOG.0000192397.41191.fb. View

Garland S, Hernandez-Avila M, Wheeler C, Perez G, Harper D, Leodolter S . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356(19):1928-43. DOI: 10.1056/NEJMoa061760. View

. Statement on human papillomavirus vaccine. An Advisory Committee Statement (ACS). Can Commun Dis Rep. 2007; 33(ACS-2):1-31. View

Schmiedeskamp M, Kockler D . Human papillomavirus vaccines. Ann Pharmacother. 2006; 40(7-8):1344-52. DOI: 10.1345/aph.1G723. View

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

Villa L, Costa R, Petta C, Andrade R, Paavonen J, Iversen O . High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006; 95(11):1459-66. PMC: 2360730. DOI: 10.1038/sj.bjc.6603469. View

Villa L, Ault K, Giuliano A, Costa R, Petta C, Andrade R . Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine. 2006; 24(27-28):5571-83. DOI: 10.1016/j.vaccine.2006.04.068. View

PASS F . Vaccines for latent viruses. J Am Acad Dermatol. 1988; 18(1 Pt 2):224-6. DOI: 10.1016/s0190-9622(88)70033-x. View

10.

Villa L, Costa R, Petta C, Andrade R, Ault K, Giuliano A . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005; 6(5):271-8. DOI: 10.1016/S1470-2045(05)70101-7. View

11.

Schiffman M, Castle P . The promise of global cervical-cancer prevention. N Engl J Med. 2005; 353(20):2101-4. DOI: 10.1056/NEJMp058171. View

12.

. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356(19):1915-27. DOI: 10.1056/NEJMoa061741. View

13.

. Recommended immunization schedules for children and adolescents--United States, 2007. Pediatrics. 2007; 119(1):207-8, 3 p following 208. DOI: 10.1542/peds.2006-3309. View

14.

Mintzes B . Disease mongering in drug promotion: do governments have a regulatory role?. PLoS Med. 2006; 3(4):e198. PMC: 1434509. DOI: 10.1371/journal.pmed.0030198. View

15.

Spier R . Ethical aspects of vaccines and vaccination. Vaccine. 1998; 16(19):1788-94. PMC: 7173252. DOI: 10.1016/s0264-410x(98)00169-8. View

16.

. ACOG Committee Opinion No. 344: Human papillomavirus vaccination. Obstet Gynecol. 2006; 108(3 Pt 1):699-705. DOI: 10.1097/00006250-200609000-00047. View